StockData
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Janux Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.74+0.23 (+1.39%)

Close on Oct 19, 2026

Market cap
$1.05B
P/E (TTM)
–
Dividend yield
–

Janux Therapeutics, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Janux Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.